Pricing Log in Create free account

Assembly Biosciences, Inc. (ASMB) vs Relmada Therapeutics, Inc. (RLMD)

Assembly Biosciences, Inc. and Relmada Therapeutics, Inc. are both Biotechnology companies. Relmada Therapeutics, Inc. is the larger, with a market value of $455.5M against $405.6M — 1.1× the size. Relmada Therapeutics, Inc. has the higher net margin (0.00% vs −0.06%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Assembly Biosciences, Inc. leads on 7 and Relmada Therapeutics, Inc. on 5.

Valuation

Metric ASMB RLMD Biotechnology median
P/E n/m n/m 10.64
P/S 5.04 n/m 9.59
P/B 1.23 2.32 2.15
Price to free cash flow n/m n/m 26.07
EV/EBITDA n/m n/m 0.65
EV/Sales 0.76 n/m 9.45
Earnings yield (0.80%) (22.37%) (34.69%)
Free cash flow yield (10.23%) (26.54%) (24.02%)

Profitability

Metric ASMB RLMD Biotechnology median
Gross margin 100.00% 0.00% 65.59%
Operating margin (11.75%) 0.00% 0.00%
Net margin (0.06%) 0.00% 0.00%
Free cash flow margin (51.53%) 0.00% 0.00%
Return on equity (0.03%) (55.66%) (51.96%)
Return on assets (0.02%) (51.57%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ASMB RLMD Biotechnology median
Revenue growth (TTM) 125.12% — 4.59%
EPS growth (last fiscal year) 91.78% 45.28% 29.88%
Revenue growth, 5-year CAGR 35.27% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ASMB RLMD Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 13.99 29.52 4.86
Net debt to EBITDA 17.31 1.57 1.01

Dividend

Metric ASMB RLMD Biotechnology median
Dividend yield — — 0.38%
Payout ratio — — —

Size

Metric ASMB RLMD Biotechnology median
Market cap 405.59m 455.48m 174.29m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack